CAPA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Research and development expenses primarily consist of personnel costs and benefits, stock-based compensation, lab supplies, consulting and professional services, fabrication services, charges related to product without an alternative future

• use, facilities costs, software, and other outsourced expenses. Research and development expenses are recognized as incurred. Our research and development expenses are primarily related to developing new products and services.

• Research and development expenses for the three and six months ended June 30, 2026 and 2025 are as follows (dollars in thousands):

• Research and development expenses increased by $0.6 million, or 4.0%, for the three months ended June 30, 2026, when compared to the same period in 2025. This increase was primarily driven by a $0.6 million increase in fabrication and outsourced services driven by efforts to support the development …

• Research and development expenses increased by $1.4 million, or 4.8%, for the six months ended June 30, 2026, when compared to the same period in 2025. This increase was primarily driven by a $1.1 million increase in laboratory supplies, $0.8 million of fabrication and outsourced services driven by …

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• Research and development expenses primarily consist of personnel costs and benefits, stock-based compensation, lab supplies, consulting and professional services, fabrication services, charges related to product without an alternative future use, facilities costs, software, and other outsourced expe…

• Research and development expenses for the three months ended March 31, 2026 and 2025 are as follows (dollars in thousands):

• Research and development expenses increased by $0.8 million, or 5.6%, for the three months ended March 31, 2026, when compared to the same period in 2025. This increase was primarily driven by a $0.8 million increase in laboratory supplies, $0.3 million of payroll and payroll-related costs, $0.2 mil…

• For the three months ended March 31, 2026 and 2025, dividend income and interest income was derived primarily from fixed income securities and money market mutual funds, respectively.

• Dividend and interest income for the three months ended March 31, 2026 and 2025 is as follows (dollars in thousands):

Text added vs the prior filing · source: 10-Q · 2026-08-13

• We are exposed to market risk with respect to certain of our cash and cash equivalents and marketable securities. As of June 30, 2026, our investments are comprised primarily of investments in money market funds backed by U.S. government

• issued securities, U.S. Treasury bills, U.S. government agency bonds, high-quality corporate bonds and commercial paper. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Based on …

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• As of March 31, 2026, our marketable securities are comprised primarily of investments in money market funds backed by U.S. government issued securities, U.S. Treasury bills, U.S. government agency bonds and high-quality corporate bonds and commercial paper. The primary objective of our investments …

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Our business, results of operations, financial condition and cash flows are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 3, 2026,…

• We could fail to maintain the listing of our Class A common stock on the Nasdaq Stock Market LLC (“Nasdaq”), which could seriously harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction.

• Nasdaq has established continued listing requirements, including a requirement to maintain a minimum closing bid price of at least $1.00 per share. On July 23, 2026, we received written notice from Nasdaq notifying us that, because the closing bid price for our Class A common stock has fallen below …

• There can be no assurance that we will be able to regain compliance with the Bid Price Requirement or maintain compliance with other Nasdaq requirements in the future. If we are not able to regain and maintain compliance with Nasdaq requirements, our Class A common stock may be delisted from Nasdaq,…

• Our ProteusTM platform (“Proteus”), which was originally anticipated to be launched at the end of 2026, is now estimated to be commercially available in the second quarter of 2027. If Proteus is not launched within our updated time frame, or is delivered without the applications and capabilities our…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• On August 10, 2026, the Company committed to an organizational restructuring program (the “2026 Restructuring Program”) designed to restructure resources focused specifically on its ProteusTM development program as well as other adjustments to streamline general and administrative expenses to align …

• In connection with the 2026 Restructuring Program, on August 10, 2026, the Company and John Vieceli, Ph.D., the Company’s Chief Product Officer, mutually agreed to end their employment relationship effective August 13, 2026 (the “Separation Date”). Dr. Vieceli is subject to the Amended and Restated …

• The material terms of Dr. Vieceli’s separation are described in, and the Severance Plan is filed as, Exhibit 10.18 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which is incorporated by reference herein.